<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel>
    <title>DSpace Collection: Onkologi</title>
    <link>http://hdl.handle.net/2282/343</link>
    <description />
    <items>
      <rdf:Seq>
        <rdf:li resource="http://hdl.handle.net/2282/427" />
        <rdf:li resource="http://hdl.handle.net/2282/425" />
        <rdf:li resource="http://hdl.handle.net/2282/424" />
        <rdf:li resource="http://hdl.handle.net/2282/423" />
      </rdf:Seq>
    </items>
  </channel>
  <textInput>
    <title>The Collection's search engine</title>
    <description>Search the Channel</description>
    <name>search</name>
    <link>http://teora.hit.no:8443/dspace/simple-search</link>
  </textInput>
  <item rdf:about="http://hdl.handle.net/2282/427">
    <title>Re: Baseline findings of the Italian multicenter randomized controlled trial of "once-only sigmoidoscopy"--SCORE</title>
    <link>http://hdl.handle.net/2282/427</link>
    <description>Title: Re: Baseline findings of the Italian multicenter randomized controlled trial of "once-only sigmoidoscopy"--SCORE
&lt;br/&gt;
&lt;br/&gt;Authors: Hoff, Geir; Bretthauer, Michael; Skovlund, Eva; Grotmol, Tom
&lt;br/&gt;
&lt;br/&gt;Description: This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Journal of the National Cancer Institute following peer review. The definitive publisher-authenticated version is available online at: http://dx.doi.org/10.1093/jnci/95.14.1089</description>
  </item>
  <item rdf:about="http://hdl.handle.net/2282/425">
    <title>CRC screening: review of the evidence and suggestions on when and how to move on from randomized trials to screening programmes</title>
    <link>http://hdl.handle.net/2282/425</link>
    <description>Title: CRC screening: review of the evidence and suggestions on when and how to move on from randomized trials to screening programmes
&lt;br/&gt;
&lt;br/&gt;Authors: Hoff, Geir</description>
  </item>
  <item rdf:about="http://hdl.handle.net/2282/424">
    <title>Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT)</title>
    <link>http://hdl.handle.net/2282/424</link>
    <description>Title: Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT)
&lt;br/&gt;
&lt;br/&gt;Authors: Hoff, Geir; Grotmol, Tom; Thiis-Evensen, Espen; Bretthauer, Michael; Gondal, Ghous G.; Vatn, Morten H.
&lt;br/&gt;
&lt;br/&gt;Abstract: BACKGROUND: Screening for colorectal cancer (CRC) using guaiac based faecal occult blood tests (FOBT) has an estimated programme sensitivity of &gt;60% but &lt;30% for strictly asymptomatic CRC in a single screening round. In search for improved non-invasive tests for screening, we compared a test for faecal calprotectin (PhiCal) with a human haemoglobin immunochemical FOBT (FlexSure OBT). METHODS: In the Norwegian Colorectal Cancer Prevention (NORCCAP) trial, screenees in one screening arm were offered screening with combined flexible sigmoidoscopy (FS) and FlexSure OBT. They were also requested to bring a fresh frozen sample of stool for the PhiCal test which was performed on samples from screenees with CRC (n = 16), high risk adenoma (n = 195), low risk adenoma (n = 592), and no adenoma (n = 1518) (2321 screenees in total). A positive PhiCal test was defined by a calprotectin level &gt; or =50 microg/g. RESULTS: The PhiCal test was positive in 24-27% of screenees whether they had no adenoma, low risk adenoma, or high risk adenoma. Ten (63%) of 16 CRCs gave a positive PhiCal test. The total positivity rate in this population was 25% for the PhiCal test compared with 12% for FlexSure OBT, with a sensitivity for advanced neoplasia of 27% and 35%, respectively. Specificity for "any neoplasia" was 76% for the PhiCal test and 90% for FlexSure OBT. CONCLUSIONS: In colorectal screening, the performance of the PhiCal test on a single spot from one stool sample was poorer than a single screening round with FlexSure OBT and cannot be recommended for population screening purposes. The findings indicate a place for FlexSure OBT in FOBT screening.</description>
  </item>
  <item rdf:about="http://hdl.handle.net/2282/423">
    <title>The science and politics of colorectal cancer screening</title>
    <link>http://hdl.handle.net/2282/423</link>
    <description>Title: The science and politics of colorectal cancer screening
&lt;br/&gt;
&lt;br/&gt;Authors: Hoff, Geir; Bretthauer, Michael</description>
  </item>
</rdf:RDF>

